Brexpiprazole Effective for Long-term Adjunctive Treatment of Major Depressive Disorder
Treatment with brexpiprazole as adjunctive antidepressant therapy was safe and effective in patients with major depressive disorder.
Treatment with brexpiprazole as adjunctive antidepressant therapy was safe and effective in patients with major depressive disorder.
In pediatric patients with bipolar I depression, long-term treatment with lurasidone 20 mg/day is effective in reducing depressive symptoms.
In pediatric patients with ADHD, treatment with dasotraline 4 mg/day was effective in treating a range of ADHD-related symptoms and behaviors.
Younger patients treated with antipsychotics after experiencing a first episode of psychosis are at an increased risk for metabolic syndrome and cardiovascular disease.
Longitudinal associations between diabetes and cognitive decline have been reported.
Patients experiencing bipolar depressive episodes with and without psychosis had similar treatment responses.
Seven online tools and mobile apps were recommended in order to help healthcare workers reduce stress, burnout, depression, and suicidal behaviors.
The Clinton Foundation’s Health Matters Initiative, in partnership with the Johns Hopkins Bloomberg School of Public Health, issued a report providing 49 recommendations under 10 topic areas on how to address the opioid crisis.
Researchers identified a DNA variant—located in the DNMT3B gene—that increases likelihood of nicotine dependence. The variant is commonly found in people of European and African descent. The discovery could create possibilities into new research for nicotine addiction treatments.
People with schizophrenia have a mortality rate 3 times higher than the general population, which may be linked to higher rates of smoking, alcohol consumption, poor diet, and lack of exercise in people with schizophrenia.